This document is a program for the CBI Global Compliance Congress taking place November 18-19, 2015 in Munich, Germany. The program features panels and presentations on various topics related to compliance best practices from industry and government perspectives. Speakers include representatives from EFPIA, IFPMA, Transparency International, various pharmaceutical companies, and regulatory bodies such as the Serious Fraud Office. Breakout sessions will address issues like HCP relationships, third party oversight, transparency reporting, and challenges for small/mid-size compliance programs. An invitation-only CCO Summit is also included on both days.

1. Michael Bartke, Director,
Compliance Management, Daiichi Sankyo Europe;
Co-Chair, EFPIA Compliance Workgroup
Holger Diener, Managing Director,
Association of Voluntary Self-Regulation
for the Pharmaceutical Industry
Michel A. Dutrée, M.D. Ph.D.,
Former Director General, Nefarma
Brendan Shaw, Assistant Director General, IFPMA
Richard Bergstrom, Director General, EFPIA
Krzysztof Kaluzny, Project Manager, INFARMA
PLUS
DON’T MISS A
PANEL WITH:
R E G I S T E R A T W W W . C B I N E T . C O M / G L O B A L C O M P L I A N C E • + 1 - 3 3 9 - 2 9 8 - 2 1 0 0
for LIFE SCIENCES
18-19 NOVEMBER 2015 • SHERATON MUNICH ARABELLAPARK HOTEL • MUNICH, GERMANY
F E A T U R E D I N D U S T R Y A N D G O V E R N M E N T P E R S P E C T I V E S :
Robert Barrington
Executive Director,
Transparency International UK
Brian Beeler
Executive Vice President,
General Counsel,
Horizon Pharma
Ingrid Eberle
Compliance Officer,
Tillotts Pharma AG
Ben Morgan
Joint Head,
Bribery and Corruption,
Serious Fraud Office
Kersten Schmahl
Vice President Ethics and
Compliance, Europe, MEA,
Asia-Pac, Actavis
Leonardo Cassara A. Silva
Head of Compliance,
Acino Pharma AG
Jolanta Wyszynska
Vice President, Commercial
Compliance Europe,
AstraZeneca
Strategic Areas of Focus to Improve
Compliance Policies, Practices and
Procedures Globally, Including:
• EFPIA Code Implementation
• Due-Diligence and Oversight
• HCP Engagement
• Anti-Bribery and Corruption and FCPA
• Risk Assessments
• Enhanced Auditing and Monitoring Practices
• Emerging Risks
The Most Comprehensive 2-Day Event Dedicated to Enhancing
Your Corporate Compliance Programmes
R E G I S T E R BY 1 8 S E P T E M B E R 2 0 1 5 A N D S AV E € 2 0 0 !
CBI, a division of
UBM Life Sciences
Media Partners:CCO Summit Host:

2. Stay Current on the Evolving Regulations
Affecting Compliance Teams Across the Globe
CBI’s Global Compliance Congress continues to provide the most
comprehensive content and strategic learning objectives for life
sciences compliance professionals. Join CCOs and their legal
and compliance teams at the industry-leading event devoted to
minimising risk and enhancing overall compliance programmes
and team effectiveness.
Meet the wide-range of
compliance executives
who benefited from the
2014 Congress:
Compliance / Ethics / Risk 63%
Legal / Counsel 13%
Operations / Strategy 10%
Medical / Regulatory Affairs 8%
Consulting 6%
TOP REASONS TO ATTEND:
• Ensure comprehension of emerging codes and guidelines
across the globe including EFPIA and ABPI
• Understand the overall impact of global data privacy
regulations as it relates to internal and external data
• Review potential areas of high-risk associated with HCP
interactions post-transparency
• Gain best practices in handling third-party selection,
monitoring, removal and renewal
• Conduct effective and efficient investigations of internal and
external entities
• Analyse the importance of monitoring beyond policies
• Receive updates on the latest implications of EFPIA requirements
R E G I S T E R AT W W W. C B I N E T. C O M / G L O B A L C O M P L I A N C E • + 1 - 3 3 9 - 2 9 8 - 2 1 0 0
A GREAT PLACE TO MEET YOUR MARKET!
Take advantage of the best opportunity to meet potential clients face-to-face. Build relationships while
demonstrating thought leadership and sharing expertise. For more information on how to position your company as
a sponsor or exhibitor, contact Taylor Biggers at +1-339-298-2108 | taylor.biggers@cbinet.com
CONFERENCE SPONSORS

3. 7:45 Main Conference Registration and Continental Breakfast
8:45 Day One Chairperson’s Welcome and Opening Remarks
JolantaWyszynska,VicePresident,CommercialComplianceEurope,
AstraZeneca
9:00 INDUSTRY PANEL
Compliance as a Means to Success —
Best Practices to Promote Cohesive Global
Compliance Practices in 2015 and Beyond
• Benefit from diverse perspectives on how compliance
can be enhanced, internally, across all offices
• Foster trust and understanding of the importance
of compliance to the business
• Improve communication between the business and
compliance to deepen the culture of compliance
• Assess strategies to implement controls across
the organisation to instill values of compliance
Panelists:
KerstenSchmahl,VicePresidentEthicsandCompliance,Europe,
MEA,Asia-Pac,Actavis
AnjaVerbeke,RegionalComplianceCounsel,EMEA,Baxter
LeonardoCassaraA.Silva,HeadofCompliance,Acino Pharma AG
MarcChrishanBauer,Director,SeniorLegalCounsel,Amgen
10:00 Networking and Refreshment Break
10:30 CPME Guidelines on the Transparency of Physician
Relationships with the healthcare industry
• Understand who the CPME is and the overall
goals of the organisation
• Assess the importance of focus on transparency of physician
relationships with the healthcare industry
• Become familiar with the eighteen principles defined and
addressed by CPME
KatrínFjeldsted,President,CPME,Comité Permanent des Médecins
Européens, Standing Committee of European Doctors
10:55 STAKEHOLDER KEYNOTE
HCP and Purchaser Perspectives — Impact of
Changing Requirements and Business Models
AoifeDelmas,IndustryRelationsOfficer,
ESC — European Society of Cardiology
11:15 EFPIA KEYNOTE
EFPIA Updates for Ethics and Compliance —
2015 and Beyond
• Review the expectations placed on the industry
by EFPIA for global transparency
• Understand new and current initiatives under
way for EFPIA in 2015 and beyond
• Assess how EFPIA works with other organisations
and regulatory bodies
RichardBergstrom,DirectorGeneral, EFPIA
12:00 Networking Luncheon and Beginning
of Invitation Only CCO Summit
13:00 C h o o s e F r o m T w o B r e a k o u t s
HCP Relationship Management
Post-Reporting — Lessons
Learned from U.S. Sunshine Act
• Review best practices for collecting,
monitoring, and disclosing
HCP information
• Assess the potential impact on
relationships with HCPs, and focus
on how to maintain good
relationships, as a result of their
data being publicly available
• Evaluate how to address potential
HCP disputes about data, both
pre-and post-disclosure
• Analyse the impact of U.S. vs.
Europe entities and reporting of
HCP data on a global basis
RyanBurger,Director,TransparencyReporting,
AstraZeneca
BrianP.Sharkey,Counsel,
Porzio, Bromberg & Newman
ChristineN.Bradshaw,Counsel,Porzio
Enhance Third-Party
Oversight and Due Diligence
Programmes to Mitigate
Global Anti-Bribery and
Anti-Corruption Risks
• Best practices in handling
third-party removal and renewal
• Customise compliance practices
and training for different levels of
third-parties and their risk profile
• Revise business practices based
upon third-party oversight risks
• Conduct effective and efficient
investigations of third-parties
• Manage third-parties in high
risk areas of the world
MilenaYakimova,DirectorEthics
&ComplianceCEE&SEE, Actavis
AndyBender,PresidentandFounder,Polaris
TamaraTubin,CorporateComplianceDirector,
International,Biogen
INVITATION-ONLY
CCO Summit*
12:15 Lunch
13:30 Summit Host Welcome and
Anti-Trust Guideline Reminders
This Summit is designed to encourage
an open exchange of ideas and strategies
surrounding some of the most critical
issues facing Chief Compliance Officers,
their programmes and teams across
the life sciences industry. Facilitators
lead discussions surrounding common
questions, challenges and issues
facing CCOs today. Participants benefit
from exclusive networking with peers in
similar positions, share challenges and
pose questions of their colleagues to
come away with valuable insight into
current and future compliance initiatives.
R E G I S T E R AT W W W. C B I N E T. C O M / G L O B A L C O M P L I A N C E • + 1 - 3 3 9 - 2 9 8 - 2 1 0 0
breakout a breakout b
DAY ONE WEDNESDAY, 18 NOVEMBER 2015
Hosted by:

4. R E G I S T E R AT W W W. C B I N E T. C O M / G L O B A L C O M P L I A N C E • + 1 - 3 3 9 - 2 9 8 - 2 1 0 0
15:00 C h o o s e F r o m T w o B r e a k o u t s
Small to Mid-Size Compliance
Programme Master Class
• Review issues unique to small
compliance organisations
• Assess issues with resource
allocation surrounding areas
of high-risk
• Discuss best practices to ensure
compliance with limited
team numbers
• Create strategies to communicate
the importance of compliance to
top-level executives
KatrinaChurch,JD,
GlobalComplianceOfficer,
Merz Pharma GmbH & Co. KGaA
IngridEberle,ComplianceOfficer,
Tillotts Pharma AG
TimothyAyers,ChiefComplianceOfficer,
Horizon Pharma
Cross Border Engagements,
International Scientific
Congresses and
Interactions with HCPs
and Their Challenges
• Discuss considerations for FMV
across country lines in the
current environment
• Assess the risks associated with
speaker programmes as well as
sponsorship opportunities
• Analyse potential FCPA issues
caused by cross-border activities
• Overcome challenges associated
with interactions between HCPs
and field forces
• Review potential areas of high-risk
associated with HCP interactions
post-Open Payments reporting data
Christian-ClausRoth,GlobalMedicalAffairs,
HeadofGlobalEventGovernance,
Novartis Pharma AG; Co-Presidentof
IPCAA (International Pharmaceutical
Congress Advisory Association)
DumitruUta,EthicsandComplianceDirector,
Lilly South-East Europe
INVITATION-ONLY
CCO Summit*
An antitrust attorney is present
throughout the Summit to ensure
appropriate and compliant
discussion among participants.
TOPICS FOR DISCUSSION:
I. FCPA and Due Diligence
II. Transparency and Open
Payments
III. HCP Relationships
IV. Global Anti-Bribery Corruption
JolantaWyszynska,VicePresident,Commercial
ComplianceEurope,AstraZeneca
Marc-OliverLamaro,ChiefComplianceOfficer,
Sanofi Pasteur MSD
*Invited participants hold the title of Chief
Compliance Officer, Vice President of Compliance,
General Counsel or an equivalent compliance
leadership position at a life sciences company
(at the time of the conference). Final eligibility
approval is at the discretion of CBI.
breakout c breakout d Cont’d
16:30 Close of Day One
Networking Wine and Cheese Commences at the Close of Day One
About Our CCO Summit Host: Porzio Life Sciences, LLC (PorzioLS) provides the life sciences
industry with Internet-based products enabling companies to comply with marketing and sales federal
and state laws and regulations, as well as, distribution licensing, sampling and a growing body of state
life sciences compliance requirements. PorzioLS provides compliance tools and customized services,
related to the PDMA, anti-kickback statutes, aggregate spend reporting, OIG and CMS guidances, OPDP
promotional violations, False Claims Act and FDA regulations, such as the Porzio Compliance Digest and
Porzio AggregateSpendID, a best in class aggregate spend system capable of handling state and federal
transparency reporting and dispute resolutions, in addition to sample transparency reporting.
Porzio AggregateSpendID streamlines state and federal marketing disclosures by automating the collection and accurate reporting of
expenses directed to healthcare practitioners and organisations. The searchable databases of the Porzio Compliance Digest cover drug and
device distribution licensing, transparency legislation, sample and trade product distribution and trends in government investigations.
Through our Distribution Licensing Services, we identify and attain all required licenses based on a company’s unique distribution model.
Finally, our formula-based approach to sample accountability, Significant Loss Threshold Assurance, ensures that customers neither over or
under report sample losses. These compliance tools and customized services facilitate companies’ compliance with federal and state marketing
and sales regulations, which has propelled PorzioLS into an industry leader in life sciences marketing and sales compliance.
The International Life Sciences Transparency Database provides guidance on non-US disclosure requirements pertaining to interactions with
HCPs and HCOs and provides easy-to-read excerpts and summaries (in English) on crucial global information including, non-US reporting
requirements concerning HCP/HCO transfers of value, anti-bribery and anti-corruption, prohibitions and financial limitations on HCP/HCO
interactions and data privacy. The International Database also contains EFPIA, Eucomed, IFPMA and Mecomed international industry and
member association codes.
Strengthen your compliance programme today by visiting www.porziolifesciences.com or contacting us +1-877-477-7411.
14:30 Networking and Refreshment Break

5. 7:45 Main Conference Registration
and Continental Breakfast
8:15 Day Two Chairperson’s Welcome
and Review of Day One
MichaelBartke,Director,ComplianceManagement,Daiichi Sankyo
Europe;Co-Chair,EFPIA Compliance Workgroup
8:20 KEYNOTE PANEL
Global Transparency of HCP Data —
The Current Environment and Future
Direction of Disclosure Code
• Analyse how different codes and countries
are approaching HCP spend reporting
• Obtain guidance based on crucial components
of various local requirements
• Gain varying regional and local insights into
guidelines surrounding transparency of HCP data
Moderator:
BrianP.Sharkey,Counsel,Porzio, Bromberg & Newman
Panelists:
MichaelBartke,Director,ComplianceManagement,
Daiichi Sankyo Europe;
Co-Chair,EFPIA Compliance Workgroup
HolgerDiener,ManagingDirector,
Association of Voluntary Self-Regulation for the
Pharmaceutical Industry
MichelA.DutréeMD,Ph.D.,FormerDirectorGeneral,Nefarma
BrendanShaw,AssistantDirectorGeneral,IFPMA
RichardBergstrom,DirectorGeneral,EFPIA
KrzysztofKaluzny,ProjectManager,INFARMA
9:10 KEYNOTE ADDRESS
Looking Beyond FCPA — Emerging Areas of Risk
• Review areas of high-risk beyond
straightforward bribery cases
• Benefit from data and metrics indicating current
future areas of focus to prevent corruption
• Assess what issues may affect the industry over
the next five years and into the future, including
sales and lobbying practices
RobertBarrington,ExecutiveDirector,
Transparency International UK
9:40 SERIOUS FRAUD OFFICE KEYNOTE
Global Update on Anti-Bribery and Corruption
Efforts — Identifying Risk Areas, New National
and Global Anti-Corruption Guidelines
• Strengthen understanding of anti-bribery and
corruption efforts from regulatory bodies
• Discuss emerging areas of risk unveiled by
recent cases and new regulations
• Optimise internal cooperation and understanding
to adhere to new and emerging regulations across
the globe
BenMorgan,JointHead,BriberyandCorruption,
Serious Fraud Office
10:20 Networking and Refreshment Break
R E G I S T E R AT W W W. C B I N E T. C O M / G L O B A L C O M P L I A N C E • + 1 - 3 3 9 - 2 9 8 - 2 1 0 0
DAY TWO
THURSDAY, 19 NOVEMBER 2015
WHO SHOULD ATTEND
You will benefit from attending this event if you are a Chief Compliance Officer, General Counsel or senior-level professional
or team member at a life sciences company with responsibilities or involvement in the following areas:
Compliance and Ethics • Legal Affairs • Transparency • Internal Audit
Monitoring • Investigations • Training • Medical Affairs
This conference will also benefit laws firms, consultants and IROs who supply the industry with assistance in regulatory,
compliance and legal challenges, audit services, monitoring programmes and CIA implementation plans, as well as
technology providers with transparency and open payments or customer master solutions.

6. 12:20 Networking Luncheon
R E G I S T E R AT W W W. C B I N E T. C O M / G L O B A L C O M P L I A N C E • + 1 - 3 3 9 - 2 9 8 - 2 1 0 0
10:50 C h o o s e f r o m T h r e e C o m p r e h e n s i v e T o p i c I n t e n s i v e s
Stakeholder
Engagement —
Overcome Complexities
in Interactions with HCPs
10:50 Track Chair’s
Opening Remarks
11:00 Implement a Global
FMV Programme in
Tandem with Evolving
Transparency Regulations
• Discuss challenges of FMV
standardisation across
cultures and economies
• Understand global
complexities and integrate
them into your
FMV calculations
• Assess transparency
regulations as they pertain
to FMV calculations for HCPs
KatalinPungor,
HealthCareComplianceOfficer,
Johnson & Johnson
11:40 Create a Holistic Approach
to Global Medical Affairs
Compliance to Decrease
Risk and Enhance
Internal Cooperation
• Review best practices to
assembling a compliance
program to monitor
medical affairs
• Assess the role of
medical affairs in
global organizations
• Build effective compliance
policies for cross-border
MSL and medical affairs
interactions
KevinEspinoza,GlobalVicePresident,
DeputyEthicsandComplianceOfficer,
BTG International, Inc.
Improve Internal
Collaboration to
Optimise Global
Compliance Success
10:50 Track Chair’s
Opening Remarks
11:00 Enhance Communication
Between Legal and
Compliance to
Improve Collaboration
• Discuss how legal and
compliance work together
• Assess the role of compliance
vs. the role of legal
• Analyse some of the major
challenges affecting
collaboration between
these two departments
TimothyAyers,
ChiefComplianceOfficer,
Horizon Pharma
BrianBeeler,
ExecutiveVicePresident,GeneralCounsel,
Horizon Pharma
11:40 Implement Effective
Tactics to Build Global
Compliance Programmes
to Decrease FCPA Risk
• Discuss different challenges
affecting regions such as
Europe, China, Russia,
Latin America
• Build strategies to prevent
risk for different cultures
• Understand the difference
in procedures built for
different regions
TOPIC 1 TOPIC 2
Global Anti-Bribery
and Corruption —
Mitigate Risk in
Emerging Markets
10:50 Track Chair’s
Opening Remarks
11:00 Enhance Processes across
the Business to Mitigate
Anti-Bribery and Corruption
Risks in Emerging Markets
• Manage risks unique to
emerging markets
• Analyse the impact of the
political climate and
culture on processes
• Identify strategies to
enhance relationships
with third-parties in
emerging markets
NaderKhedr,Ph.D.,MBA,
HeadRegionalCompliance—
MiddleEastandAfrica,
Sandoz Regional Office —
Dubai — UAE
Anne-MarieZell,Associate,
AdvisoryServices,TRACE
11:40 Strategies to Improve
Third-Party Distributor
Oversight and Compliance
• Identify factors unique
to distributors and best
practices to minimise risks
• Audit third-parties
and sub-contractors to
ensure business partners
remain compliant
• Maintain compliance
with contracts across
global distributors
• Understand the impact
of effective compliance
oversight of distributors
in emerging markets
UlfH.Grundmann,Partner,
King & Spalding
TOPIC 3

7. R E G I S T E R AT W W W. C B I N E T. C O M / G L O B A L C O M P L I A N C E • + 1 - 3 3 9 - 2 9 8 - 2 1 0 0
13:20 C h o o s e f r o m T h r e e C o m p r e h e n s i v e T o p i c I n t e n s i v e s
Global Transparency
Reporting of
HCP Payments
13:20 Track Chair’s
Opening Remarks
13:30 Reflection on 2015 —
Updates from
Implementation of
EFPIA Requirements
• Discuss challenges
associated with data
capture procedures across
affiliated organisations
• Analyse different
opportunities streamline
implementation internally
• Assess best practices behind
unifying matching and
comparing cross-border
spend across country lines
LaurentClerc,
RegulatoryAffairsExpert,
BMI SYSTEM
14:10 Strategies to Implement
EFPIA Requirements Across
the Organisation
• Review a case study
on the process of
EFPIA requirement
implementations
* leverage lessons learned
and identify possible
best practices
• Explore road blocks and
challenges faced
throughout implementation
DinorahVelez,CISA,Director,
EFPIATransparencyReporting,
Pfizer Inc
Compliance Programme
Enhancement
13:20 Track Chair’s
Opening Remarks
IanStorey,SeniorDirector,Compliance,
AstraZeneca
13:30 Strategies for
Comprehensive
Training to Improve
Compliance Excellence
• Discuss practical training
strategies to enhance
compliance across
the business
• Utilise creative training
practices to engage trainees
and improve retention
• Assess training policies for
internal and external
business partners
AndrewHo,CountryComplianceOfficer,
AustraliaandNewZealand,Sanofi
14:10 Building Blocks of
Successful Compliance
Programmes — Skills to
Enhance Compliance Teams
• Identify areas of expertise
around compliance that are
not often associated with
compliance officers and
their teams
• Discuss the importance
of negotiation, team
building and stakeholder
communication skills
• Assess the importance of
enhancing ‘soft’ skills that
surround compliance and
promote success
JoeKent,ChiefComplianceOfficer,
Takeda
TOPIC 4 TOPIC 5
Auditing, Monitoring
and Risk Assessment
13:20 Track Chair’s
Opening Remarks
13:30 BI Italy Compliance
Governance Approach —
Risk Assessment and
Management of HCP
Consultancy and
Fee-for-Services
• Enhance monitoring and
auditing practices by learning
from mistakes and reinforcing
compliance expertise
• Analyse interactions with HCPs
to ensure fair fee-for-services
• Assess compliance risks
associated with HCP
management and the
importance of thorough
risk assessments
GiuseppePalmieri,DAF/Risk&Compliance
ManagementandAudit,HeadofRisk&
ComplianceManagementandAudit
ChairmanofSupervisoryBody(OdV)
BI Italia, Boehringer Ingelheim
Italia S.p.A. — Milano
14:10 Best Practices for
Internal Auditing and
Monitoring Processes
• Understand the importance
of effective self-monitoring
• Analyse the difference
between auditing
and monitoring
• Review strategies to
internally monitor across
business entities
KellyHawson,UKComplianceOfficer,
Mundipharma
TOPIC 6
CASE
STUDY
14:50 Close of Congress

8. WEB
www.cbinet.com/
globalcompliance
EMAIL
cbireg@cbinet.com
PHONE
800-817-8601
+1-339-298-2100 outside the U.S.
LIVE CHAT
www.cbinet.com/
globalcompliance
WAYS TO REGISTER NOW!
CBI
70 Blanchard Road
Burlington, MA 01803
CBI, a division of
UBM Life Sciences
Global Compliance Congress for Life Sciences PC15284
VENUE:
Sheraton Munich Arabellapark Hotel
Arabellastrasse 5
81925 Munich, Germany
Phone Reservations: 00800 32 53 53 53
Hotel Direct Line: +49 89 9232 0
ACCOMMODATIONS:
To receive CBI’s special discounted hotel rate online or by phone, please go to:
• Online: www.cbinet.com/globalcompliance
• Phone reservations: 00800 32 53 53 53 and mention CBI’s Global Compliance.
Book Now! The Sheraton Munich Arabellapark Hotel is accepting reservations on a
space and rate availability basis. Rooms are limited, so please book early. All travel
arrangements subject to availability.
PLEASE NOTE: All hotel reservations for this conference should be booked directly
with the hotel. CBI does not use Housing Bureaus and none are authorised to call
on our behalf.
REGISTRATION FEE:
Register by 18 September 2015 and SAVE €200. Fee includes continental breakfast, lunch,
wine and cheese reception, refreshments and conference documentation. Please make checks
(in U.S. funds drawn on a U.S. bank) payable to: CBI. (No personal checks accepted.)
PLEASE NOTE: All advertised discounts are taken from the full, Standard Rate.
TEAM DISCOUNT:
For every three paying registrations from your company, you will receive a fourth complimentary*
registration to the conference (must register four at same time to qualify). To receive the team discount
you must register with our customer service department by calling +1-339-298-2100.
* Advantage pricing rates do apply when applicable. Offer may not be combined with any other
special pricing promotions. Offer may be used at CBI co-located events.
SATISFACTION GUARANTEED:
CBI stands behind the quality of its conferences. If you are not satisfied with the quality of the conference,
a credit will be awarded towards a comparable CBI conference of your choice. Please contact
800-817-8601 for further information. Advanced preparation for CBI conferences is not required.
SUBSTITUTION AND CANCELLATION:
Your registration may be transferred to a member of your organisation up to 24 hours in advance of the
conference. Cancellations received in writing on or before 14 days prior to the start date of the event
will be refunded, less a $399 administrative charge. No refunds will be made after this date; however,
the registration fee less the $399 administrative charge can be credited to another CBI conference if
you register within 30 days from the date of this conference to an alternative CBI conference scheduled
within the next six months. In case of conference cancellation, CBI’s liability is limited to refund of the
conference registration fee only. CBI reserves the right to alter this me without prior notice. Please
Note: Speakers and agenda are subject to change. In the event of a speaker cancellation, every effort to
find a suitable replacement will be made without notice. The opinions of the conference faculty do not
necessarily reflect those of the companies they represent or CBI.
R E G I S T E R BY 1 8 S E P T E M B E R 2 0 1 5 A N D S AV E € 2 0 0 !
REGISTER BY
19 JUNE 2015
REGISTER BY
18 SEPTEMBER 2015
REGISTER BY
18 NOVEMBER 2015
ONSITE
2-Day Conference €1,400 (+19% VAT) €1600 + 19% VAT €1800 + 19% VAT €1900 + 19% VAT
R E G I S T E R A T W W W . C B I N E T . C O M / G L O B A L C O M P L I A N C E • + 1 - 3 3 9 - 2 9 8 - 2 1 0 0
for LIFE SCIENCES
18-19 NOVEMBER 2015 • SHERATON MUNICH ARABELLAPARK HOTEL • MUNICH, GERMANY
SCAN HERE
ANY QUESTIONS OR TO REGISTER
CALL Roberts Apse 339-298-2290
or FAX TO MY ATTENTION 781-939-2459
email: roberts.apse@cbinet.com